Navigation Links
ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
Date:4/21/2008

MEMPHIS, Tenn., April 21 /PRNewswire/ -- On Tuesday, April 15th, Lee S. Schwartzberg, MD, FACP, President of the Accelerated Community Oncology Research Network, Inc. presented findings at the American Association for Cancer Research annual meeting in San Diego. The Phase II study tested a novel biologic agent in conjunction with chemotherapy used in colorectal cancer with encouraging interim results. More specifically, this Phase II study was a biomarker and genomic correlative study of GFL: Interferon Gamma, Bolus/Infusion 5-FU and Leucovorin for Metastatic Colorectal Cancer. The study represented a unique collaboration in transitional research between The West Clinic, a community-based oncology clinic in Memphis; researchers at St. Jude Children's Hospital, Memphis; and Cincinnati Children's Hospital.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/CLM151LOGO )

Utilizing its centralized services, ACORN provided access, medical and scientific oversight, statistical and project management, and publication processes for the study. In addition to promising results, ACORN's ability to provide tumor samples for genetic analysis before and after the therapy, based upon its extensive experience in interventional radiology, makes it one of a select few institutions capable of providing such samples which are playing an ever increasing role in the development of personalized medicine.

Study objectives sought to determine response rate as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines established by the National Cancer Institute, Progression Free Survival (PFS), and molecular correlates of GFL therapy.

55% of the study's participants were male and 45% female. African- Americans accounted for 21% of the participants with the remaining identified as Caucasian. The minority participation figure is well-above national norms and reflects ACORN's commitment to make advanced clinical research available to every member of the community who has a need.

Neutropenia (low white blood counts) and fatigue were the two most commonly reported side effects; however, no patients withdrew from the study as a result of any side effect.

The researchers concluded that GFL has promising clinical activity as assessed by response rates compared to historical controls of 5-FU/LV with the same dose and schedule. Furthermore, the lack of additional toxicity allows other drugs to be added to the treatment. Additional correlative studies are in progress as a result of these findings.

According to Steve Coplon, CEO, "ACORN continues to facilitate multiple opportunities linking the best thought leaders from the academic community with leading community oncologists who are committed to advancing the war on cancer in busy clinics across the nation. Given our capabilities in CRO, Network, and our own initiated trials, the results of these efforts are regularly highlighted at important meetings such as AACR, ASCO, ASH, San Antonio Breast, and other noteworthy venues."

For additional information visit http://www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.

Accelerated Community Oncology Research Network, Inc. (ACORN)

ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Clinical Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.

Contact Information:

Liz Conway

(901) 435-5570

lconway@sosacorn.com

http://www.ACORNresearch.net

Deborah D. Coble

901-683-0055x1312

Cell: 901-831-1010

dcoble@sosacorn.com


'/>"/>
SOURCE Accelerated Community Oncology Research Network, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ACORNs Oncology-focused Contract Research Organization Exceeds Projections
2. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
3. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
6. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
7. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
8. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
11. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):